MedTrace Logo

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2020-09-09

No results posted yet for this study

Summary

To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.

Conditions

Interventions

OTHER

Plasma collection

We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.

Sponsors & Collaborators

Principal Investigators

  • Robert Lewandowski, MD · Northwestern University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-05
Primary Completion
2020-01-06
Completion
2020-01-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203837 on ClinicalTrials.gov